FDA Approves TRANEXAMIC ACID — XGen Pharmaceuticals DJB, Inc.

XGen Pharmaceuticals DJB, Inc. has received FDA approval for the intravenous formulation of tranexamic acid via ANDA 201580, enhancing the company’s portfolio of hemostatic agents and offering a lower-cost alternative to ensure continued patient access. This generic entry triggers key commercial opportunities in the treatment of hemorrhaging, likely pressuring market pricing and intensifying competitive dynamics with current branded offerings.